FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
October 10, 2025
Previous PostMedincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)
Next PostTeva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
